Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act
2025 · 4th Quarter (Oct 1 - Dec 31)
ELI LILLY AND COMPANY
Filed by BROWNSTEIN HYATT FARBER SCHRECK, LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 17, 2026
- Income
- $90,000.00
- Expenses
- Not reported
- Registrant
- BROWNSTEIN HYATT FARBER SCHRECK, LLP
- Client
- ELI LILLY AND COMPANY
- Filing UUID
- 60feb010-bad2-4980-8b21-3d8d9b9b0e9c
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.